San Francisco, CA, United States of America

Michael G Johnson

This inventor holds 29 USPTO granted patents and 12 published patent applications and 7 EPO patents, primarily in Cancer Therapeutics. Top assignees: Amgen Inc., Chempartner Corporation, The University of Texas System. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael G Johnson. Retrieved from https://idiyas.com/inventor/michael-g-johnson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 29 (Patent Applications = 12)

% Patents Active = 89.7

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 7.7

ph-index = 8

Forward Citations = 272(Granted Patents)

Company Filing History:

Chempartner Corporation

patents

7 out of 5,640

The University of Texas System

Vincere Biosciences, Inc.

where one patent can have more than one assignee

Years Active: 2004-2026

Loading Chart...

Areas of Expertise:

USP30 Inhibitors

MCL-1 Protein

Bisamide Compounds

ATR Kinase

Piperidinone Derivatives

MDM2 Inhibitors

Quinoline Derivatives

CXCR3 Antagonists

Heterocyclic Compounds

Asthma Treatments

Immunoregulatory Disorders

Oxazole Compounds

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12643852 - USP30 inhibitors and uses thereof (2026-06-02),

2. 12091425 - Compounds that inhibit MCL-1 protein (2024-09-17),

3. 11845724 - USP30 inhibitors and uses thereof (2023-12-19),

4. 11780826 - Bisamide sarcomere activating compounds and uses thereof (2023-10-10),

5. 11434233 - Heterocyclic inhibitors of ATR kinase (2022-09-06),

6. 11306107 - Compounds that inhibit MCL-1 protein (2022-04-19),

7. 11299479 - Bisamide sarcomere activating compounds and uses thereof (2022-04-12),

8. 10899746 - Bisamide sarcomere activating compounds and uses thereof (2021-01-26),

9. 10894052 - Heterocyclic inhibitors of ATR kinase (2021-01-19),

10. 10800774 - Heterocyclic inhibitors of ATR kinase (2020-10-13),

11. 10800769 - Heterocyclic inhibitors of ATR kinase (2020-10-13),

12. 10745420 - Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase (2020-08-18),

13. 10723720 - Bisamide sarcomere activating compounds and uses therof (2020-07-28),

14. 10421765 - Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase (2019-09-24),

15. 10392376 - Heterocyclic inhibitors of ATR kinase (2019-08-27),

Title: Innovations and Contributions of Michael G Johnson in Cancer Research

Introduction

Michael G Johnson is a notable inventor and researcher based in San Francisco, CA. With an impressive portfolio comprising 28 patents, Johnson has significantly contributed to the field of cancer research through his innovative solutions. His inventions focus on developing compounds that target specific proteins involved in cancer progression, making strides in the fight against serious health conditions.

Latest Patents

Among his latest patents, Johnson has explored several groundbreaking inventions. One of his prominent patents includes compounds that inhibit the MCL-1 protein, which plays a critical role in the survival of cancer cells. This invention provides methods for preparing these inhibitors, related pharmaceutical compositions, and their applications in treating various diseases, particularly cancer. Another significant patent relates to USP30 inhibitors, which detail compounds, their compositions, and methods to inhibit USP30, addressing disorders mediated by this protein.

Career Highlights

Throughout his illustrious career, Michael G Johnson has been associated with prestigious organizations such as Amgen Inc. and the University of Texas System. His positions within these institutions have provided him with a platform to advance his research and enhance the development of novel therapeutic agents aimed at combating cancer.

Collaborations

In his journey, Johnson has collaborated with talented scientists including Julio Cesar Medina and Felix Gonzalez Lopez De Turiso. These collaborations have propelled his research further, fostering an environment of shared knowledge and innovation in the realm of cancer treatment.

Conclusion

Michael G Johnson’s contributions to cancer research and his considerable number of patents underscore his role as an influential inventor in the pharmaceutical field. His innovative approaches to targeting cancer-related proteins reflect a dedicated pursuit of advancements that potentially lead to more effective therapies for patients battling cancer.

Profile summary based on public USPTO records.